[Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].

Rosenthal, E; Delaunay, P; Jeandel, P-Y; Haas, H; Pomares-Estran, C; Marty, P

[Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]. / Le traitement de la leishmaniose viscérale en Europe en 2009. Place de l'amphotéricine B liposomale.

Rosenthal, E; Delaunay, P; Jeandel, P-Y; Haas, H; Pomares-Estran, C; Marty, P.

Affiliation

Rosenthal E; Service de médecine interne, centre hospitalier universitaire de Nice et université de Nice Sophia-Antipolis, France. rosenthal.e@chu-nice.fr

Med Mal Infect ; 39(10): 741-4, 2009 Oct.

Article in Fr | MEDLINE | ID: mdl-19783391

Subject(s)

Amphotericin B/therapeutic use; Antiprotozoal Agents/therapeutic use; Leishmaniasis, Visceral/drug therapy; Amphotericin B/economics; Animals; Antiprotozoal Agents/economics; Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Resistance; Europe/epidemiology; Humans; Leishmania donovani/drug effects; Leishmaniasis, Visceral/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Amphotericin B / Leishmaniasis, Visceral / Antiprotozoal Agents Type of study: Guideline / Health_economic_evaluation Limits: Animals / Humans Country/Region as subject: Europa Language: Fr Journal: Med Mal Infect Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google